Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Multisite, Randomized, Double-Blind Trial of BNT327 in Combination With Chemotherapy Versus Placebo With Chemotherapy in Patients With Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC Determined Ineligible for PD(L)1 Therapy Based on PD-L1 Negative Disease

NCT07173751 is registered in ClinicalTrials.gov with BioNTech SE as lead sponsor.

NCT NCT07173751
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07173751 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Multisite, Randomized, Double-Blind Trial of BNT327 in Combination With Chemotherapy Versus Placebo With Chemotherapy in Patients With Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC Determined Ineligible for PD(L)1 Therapy Based on PD-L1 Negative Disease
Lead sponsor
BioNTech SE
Phase
Phase 3
Overall status
Recruiting
Start date
October 30, 2025
Completion date
September 30, 2030
Enrollment
558 (estimated)
Sites
212

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms